Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Dr. Pallavi Patel College of Health Care Science, Nova Southeastern University, Fort Lauderdale, Florida.
Cancer Epidemiol Biomarkers Prev. 2023 Oct 2;32(10):1451-1457. doi: 10.1158/1055-9965.EPI-23-0543.
One of the mechanisms of ovarian tumorigenesis is through inflammation. Kidney dysfunction is associated with increased inflammation; thus, we assessed its relationship with ovarian cancer risk.
In prospectively collected samples, we evaluated the association of kidney function markers and C-reactive protein (CRP) with ovarian cancer risk in the UK Biobank. We used multivariable-adjusted Cox proportional hazards models to evaluate quartiles of serum and urine markers with ovarian cancer risk overall and by histology. We assessed effect modification by CRP (≤3.0, >3.0 mg/L).
Among 232,908 women (1,110 ovarian cancer cases diagnosed from 2006-2020), we observed no association between estimated glomerular filtration rate and ovarian cancer risk (Q4 vs. Q1: HR, 1.00; 95% confidence intervals, 0.83-1.22). Potassium was associated with endometrioid (Q4 vs. Q1: 0.33, 0.11-0.98) and clear cell (4.74, 1.39-16.16) tumors. Poor kidney function was associated with a nonsignificant increase in ovarian cancer risk among women with CRP>3.0 mg/L (e.g., uric acid Q4 vs. Q1; 1.23, 0.81-1.86), but not CRP≤3.0 mg/L (0.83, 0.66-1.05). Other associations did not vary across CRP categories.
Kidney function was not clearly associated with ovarian cancer risk. Larger studies are needed to evaluate possible histology specific associations. Given the suggestive trend for increased ovarian cancer risk in women with poor kidney function and high CRP, future work is needed, particularly in populations with a high prevalence of inflammatory conditions.
This study provided the first evaluation of markers of kidney function in relation to ovarian cancer risk.
卵巢肿瘤发生的机制之一是炎症。肾功能障碍与炎症增加有关；因此，我们评估了其与卵巢癌风险的关系。
在前瞻性收集的样本中，我们评估了英国生物库中肾功能标志物和 C 反应蛋白 (CRP) 与卵巢癌风险的关系。我们使用多变量调整的 Cox 比例风险模型来评估血清和尿液标志物的四分位数与总体和组织学的卵巢癌风险。我们评估了 CRP（≤3.0、>3.0mg/L）的效应修饰。
在 232908 名女性（2006-2020 年期间诊断出 1110 例卵巢癌病例）中，我们没有观察到估计肾小球滤过率与卵巢癌风险之间的关系（Q4 与 Q1：HR，1.00；95%置信区间，0.83-1.22）。钾与子宫内膜样（Q4 与 Q1：0.33，0.11-0.98）和透明细胞（4.74，1.39-16.16）肿瘤有关。肾功能不良与 CRP>3.0mg/L 的女性中卵巢癌风险的非显著增加相关（例如尿酸 Q4 与 Q1；1.23，0.81-1.86），但 CRP≤3.0mg/L 则不然（0.83，0.66-1.05）。其他关联在 CRP 类别之间没有变化。
肾功能与卵巢癌风险没有明显关联。需要更大的研究来评估可能的组织学特异性关联。鉴于肾功能不良和 CRP 水平高的女性卵巢癌风险增加的趋势，需要进一步的研究，特别是在炎症性疾病高发的人群中。
本研究首次评估了肾功能标志物与卵巢癌风险的关系。
